Endoscopic pancreatic duct stenting for relief of pancreatic cancer pain

Wehrmann, T.; Riphaus, A.; Frenz, M. B.; Martchenko, Ksenia; Stergiou, Nikos

doi:10.1097/00042737-200512000-00020

Cited by 34 publications

(29 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic duct obstruction resulting from the compression of pancreatic tumor causes pancreatic duct dilatation and increased pressure, thus inducing pancreatic hypertensive pain. A similar study confirmed that PD stenting achieved significant pain relief and short-term improvement of the quality of life in the majority of patients with PD obstruction due to pancreatic carcinoma (Wehrmann et al, 2005). In the present study, a large amount of pancreatic juice mixed with white protein plugs was seen after pancreatic duct drainage in the dilated duct patients.…”

Section: Discussionsupporting

confidence: 88%

Clinical Efficacy of Endoscopic Pancreatic Drainage for Pain Relief with Malignant Pancreatic Duct Obstruction

Gao

Ma²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Clinical Efficacy of Endoscopic Pancreatic Drainage for Pain Relief with Malignant Pancreatic Duct Obstruction

Gao

Ma²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Fentanyl side effects were not noted in our series, possibly because of the low dose (<0.5 mcg/kg, mean dose = 36 mcg) administered compared with that in other studies [7,32,33]. Indeed, alterations in the saturation oxygen level were not noted in the Fentanyl group, a finding consistent with the low fentanyl dose used because desaturation episodes seem to be dose-related [11,20,23].…”

Section: Discussionsupporting

confidence: 82%

“…Various pain scores use a 0-10 point scoring system as part of their evaluation. An example is the Brief Pain Inventory, which has been validated in a number of different languages and for evaluation of pain in endoscopic series [25,32].…”

Section: Methodsmentioning

confidence: 99%

Single use of fentanyl in colonoscopy is safe and effective and significantly shortens recovery time

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The main indication for pancreatic ductal stenting is "obstructive" pain related to meals in patients with a dilated main pancreatic duct beyond a stricture. However, this procedure is rarely used and the literature suggests that at most 15% of patients will have symptoms that may benefit from this intervention [14].…”

Section: Endoscopic Stenting Of Biliary and Pancreatic Obstructionmentioning

confidence: 99%

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

2008

View full text Add to dashboard Cite

Pancreatic cancer is the fourth most common cause of adult cancer death in the U.S. The high mortality rate from pancreatic cancer is a result of the high incidence of metastatic disease at the time of diagnosis, an often fulminant clinical course, and the lack of adequate systemic therapies. Unfortunately, only 5%-25% of patients present with tumors amenable to resection. The median diseasefree survival interval following resection for operable pancreatic cancer is 13.4 months for patients treated with adjuvant gemcitabine and 6.9 months for untreated patients. A much higher percentage of patients present with metastatic disease (40%-45%) or locally advanced disease (40%), and have median survival times of 3-6 months or 8 -12 months, respectively. The frustrating lack of significant clinical advancements in the treatment of metastatic pancreatic cancer remains one of medical oncology's biggest disappointments. The past decade-long frustration has resulted in regulators, investigators, and practicing oncologists gradually lowering their standards/expectations with regard to interpreting clinical trials. Two of the more important examples of this include the approval of gemcitabine plus erlotinib and the use of a progressionfree survival advantage to defend the use of gemcitabine plus oxaliplatin. Given the marginal benefit of systemic antineoplastics, a scholarly review inclusive of other palliative strategies will help oncologists optimize the care of pancreatic cancer patients. This article examines the existing evidence in support of a role for palliative therapy in metastatic pancreatic cancer, describes recent developments with newer chemotherapeutic and molecular-targeted agents, and explores future study designs. The Oncologist 2008;13:562-576

show abstract

Endoscopic pancreatic duct stenting for relief of pancreatic cancer pain

Abstract: PD stenting achieved significant pain relief and short-term improvement of the quality of life in the majority of patients with PD obstruction due to pancreatic carcinoma.

Cited by 34 publications

References 13 publications

Clinical Efficacy of Endoscopic Pancreatic Drainage for Pain Relief with Malignant Pancreatic Duct Obstruction

Clinical Efficacy of Endoscopic Pancreatic Drainage for Pain Relief with Malignant Pancreatic Duct Obstruction

Single use of fentanyl in colonoscopy is safe and effective and significantly shortens recovery time

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

Contact Info

Product

Resources

About